What is Zacks Research’s Estimate for PBH Q1 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research cut their Q1 2027 earnings estimates for Prestige Consumer Healthcare in a research note issued to investors on Tuesday, February 24th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.09 per share for the quarter, down from their prior forecast of $1.24. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2027 earnings at $4.77 EPS, Q2 2028 earnings at $1.30 EPS, Q3 2028 earnings at $1.26 EPS and FY2028 earnings at $5.06 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. During the same quarter in the prior year, the business earned $1.22 EPS. The business’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS.

PBH has been the topic of several other research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Jefferies Financial Group dropped their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $70.26 on Friday. The company has a market capitalization of $3.32 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 2.18 and a beta of 0.43. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a 12 month low of $57.25 and a 12 month high of $90.04. The stock’s 50 day moving average is $65.11 and its 200-day moving average is $63.45.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the sale, the vice president owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.40% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the company. UMB Bank n.a. increased its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at $29,000. First Horizon Corp bought a new position in shares of Prestige Consumer Healthcare in the 3rd quarter valued at $32,000. Barrow Hanley Mewhinney & Strauss LLC raised its holdings in shares of Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after buying an additional 283 shares in the last quarter. Finally, Torren Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth $35,000. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group disclosed a new stake in PBH (10,912 shares, about $681,000), signaling some institutional buying interest that can provide support to the stock. Article Title
• Neutral Sentiment: Zacks Research left a “Hold” rating and kept the consensus full‑year EPS near $4.50; a few quarterly estimates were nudged higher (Q4 2026 to $1.59, Q4 2027 to $1.32, Q3 2027 to $1.21), indicating mixed views rather than a clear upgrade.
• Negative Sentiment: Zacks cut multiple near‑term estimates, hitting Q1 2027 hardest (from $1.24 to $1.09) and trimming Q1 2028 (1.26→1.14), Q2 2028 (1.33→1.30), Q3 2028 (1.28→1.26), FY2027 (4.84→4.77) and FY2028 (5.19→5.06). Those downward revisions lower near‑term earnings expectations and are the main reason sentiment is weakening today.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).